Clinical Study of mRNA Vaccine in Patients With Liver Cancer After Operation
This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative recurrence of hepatocellular carcinoma.
Posto Perative Hepatocellular Carcinoma
DRUG: Neoantigen mRNA Personalised Cancer vaccine in combination with Stintilimab I njection
One-year recurrence-free survival rate (RFS);, 1 year|Overall survival (OS) after initial administration., 1 year
This is an open, one-arm study to evaluate the safety and efficacy of mRNA personalized tumor vaccine (tumor vaccine) encoding neonatal antigen in combination with Sintilimab injection for adjuvant prevention of postoperative recurrence of hepatocellular carcinoma.